Amended Statement of Beneficial Ownership (3/a)
15 Aprile 2022 - 11:08PM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Weld Gwen E |
2. Date of Event Requiring Statement (MM/DD/YYYY)
4/11/2022
|
3. Issuer Name and Ticker or Trading Symbol
Nautilus Biotechnology, Inc. [NAUT]
|
(Last)
(First)
(Middle)
C/O NAUTILUS BIOTECHNOLOGY, INC., 2701 EASTLAKE AVENUE EAST |
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director _____ 10% Owner ___X___ Officer (give title below) _____ Other (specify below) Chief People Officer / |
(Street)
SEATTLE, WA 98102
(City)
(State)
(Zip)
| 5. If Amendment, Date Original Filed(MM/DD/YYYY) 4/13/2022
| 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 4) | 2. Date Exercisable and Expiration Date (MM/DD/YYYY) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Stock Option (Right to Buy) | (1) | 10/15/2030 | Common Stock | 4535.0 | $1.14 | D | |
Explanation of Responses: |
(1) | Subject to reporting person's continuous status as a "Service Provider" (as defined in the Nautilus Subsidiary, Inc. 2017 Equity Incentive Plan (the "Plan")) through each vesting date, one twenty-fourth (1/24th) of the shares subject to the Option shall vest each month over the twenty-four (24) months following the Vesting Commencement Date (as defined below) on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement Date is September 29, 2020. |
Remarks: Form 3 amended to reflect stock option held by reporting person. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Weld Gwen E C/O NAUTILUS BIOTECHNOLOGY, INC. 2701 EASTLAKE AVENUE EAST SEATTLE, WA 98102 |
|
| Chief People Officer |
|
Signatures
|
/s/ Matthew B. Murphy, as Attorney-in-Fact | | 4/15/2022 |
**Signature of Reporting Person | Date |
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. |
* | If the form is filed by more than one reporting person, see Instruction 5(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
Note: | File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. |
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
Grafico Azioni ARYA Sciences Acquistion... (NASDAQ:ARYA)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni ARYA Sciences Acquistion... (NASDAQ:ARYA)
Storico
Da Giu 2023 a Giu 2024
Notizie in Tempo Reale relative a ARYA Sciences Acquistion Corporation III (NASDAQ): 0 articoli recenti
Più Nautilus Biotechnology, Inc. Articoli Notizie